nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

Open Access 01.06.2023 | Original Article

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

verfasst von: Jacopo Millul, Lennart Koepke, Gaonkar Raghuvir Haridas, Konstantin M. J. Sparrer, Rosalba Mansi, Melpomeni Fani

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2023

Abstract

Purpose

Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison has never been done. With the aim to identify strengths and limitations of the suggested strategies, we compared the monomer FAPI-46 versus (a) its dimer (FAPI-46-F1D), (b) two albumin binders conjugates (FAPI-46-Ibu (ibuprofen) and FAPI-46-EB (Evans Blue)), and (c) cyclic peptide FAP-2286.

Methods

¹⁷⁷Lu-labeled ligands were evaluated in vitro in cell lines with low (HT-1080.hFAP) and high (HEK-293.hFAP) humanFAP expression. SPECT/CT imaging and biodistribution studies were conducted in HT-1080.hFAP and HEK-293.hFAP xenografts. The areas under the curve (AUC) of the tumor uptake and tumor-to-critical-organs ratios and the absorbed doses were estimated.

Results

Radioligands showed IC₅₀ in the picomolar range. Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [¹⁷⁷Lu]Lu-FAPI-46-based radioligands showed similar uptake between the two tumor models. [¹⁷⁷Lu]Lu-FAP-2286 showed higher uptake in HEK-293.hFAP and the least background. The AUC of the tumor uptake and absorbed dose was higher for [¹⁷⁷Lu]Lu-FAPI-46-F1D and the two albumin binder conjugates, [¹⁷⁷Lu]Lu-FAPI-46-Ibu and [¹⁷⁷Lu]Lu-FAPI-46-EB, in HT1080.hFAP xenografts and for [¹⁷⁷Lu]Lu-FAPI-46-EB and [¹⁷⁷Lu]Lu-FAP-2286 in HEK293.hFAP xenografts. The tumor-to-critical-organs AUC values and the absorbed doses were in favor of [¹⁷⁷Lu]Lu-FAP-2286, but tumor-to-kidneys.

Conclusion

The study indicated dimerization and cyclic peptide structures as promising strategies for prolonging tumor residence time, sparing healthy tissues. Albumin binding strategy outcome depended on the albumin binding moiety. The peptide showed advantages in terms of tumor-to-background ratios, besides tumor-to-kidneys, but its tumor uptake was FAP expression–dependent.

Supplementary file1 (PDF 1.30 MB)

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1007/s00259-023-06272-7.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

The tumor microenvironment (TME) is a complex fundamental part of solid tumors [1] whose composition is different among patients. Nevertheless, there are common phenotype analogies among individuals [2, 3]. Stromal cells and extracellular matrix are the main component of the TME, in which cellular infiltrates such as lymphocytes, macrophages, adipocytes, and fibroblasts are present [1]. Cancer-associated fibroblast (CAF) is one of the most abundant cell type in the TME, heavily contributing to the whole tumor mass [4]. CAFs are characterized by the expression of fibroblast activation protein-α (FAP), which is a type II transmembrane serine protease found in more than 90% of epithelial tumors such as breast, lung, colorectal, pancreatic, and ovarian cancer. FAP expression in healthy tissues and in non-malignant tissues surrounding the tumor is very limited, as confirmed by immunohistochemistry [5, 6]. Thus, FAP has recently been identified as a pan-tumoral agent. A class of small molecule–based radioligands targeting FAP has emerged in the last few years for imaging of solid tumors [7, 8]. The value of these radioligands has been illustrated in more than one hundred patients with unprecedented tumor-to-organ selectivity. Thus, FAP-targeting radioligands have been recently dubbed “potential novel molecule(s) of the century” [8, 9].

While their potential as imaging agents is undeniable, their potential for therapy is harmed by the short retention in the tumor, leading to suboptimal tumor radiation doses and, thus, limited efficacy [7, 1310-]. A promising strategy to improve the tumor retention is via the increase of radioligand’s avidity for its target by dimerization of the binding moiety [14-16]. Another strategy involves the introduction of an albumin binder moiety, such as Evans Blue, which increase the exposure of the tumor to the radioligand due to its higher blood circulation [17, 18]. Alternatively, first-in-human results of the cyclic peptidic structure [¹⁷⁷Lu]Lu-FAP-2286 showed high and persistent uptake in primary and metastatic tumor [19, 20].

While many preclinical and first-in-human clinical data have been generated with these radioligands, a comprehensive, comparative study to understand the strengths and limitations among the mentioned strategies has never been performed.

Here, we compared head-to-head representative FAP-targeting radioligands from each strategy that was proposed to prolong tumor residence time. More specifically, using [¹⁷⁷Lu]Lu-FAPI-46 as the reference small molecule, we compared it with (a) a dimeric version of it, (b) two conjugates of it with different albumin binders, and (c) the [¹⁷⁷Lu]Lu-FAP-2286, as the representative peptide-based radioligand. Head-to-head in vitro and in vivo assessments were performed using two cell lines characterized by low and high FAP expression, respectively. Our aim was to identify the strengths and limitations of the different strategies, namely, dimerization, albumin binder conjugation, and peptides vs small-molecule monomers, for the development of FAP-targeting radiotherapeutics.

Material and methods

Synthesis, radiolabeling, and log D determination

FAPI-46, FAPI-46-F1 (a positive control), FAPI-46-F1D, FAPI-46-Ibu, FAPI-46-F1-EB, and FAP-2286, all conjugated to DOTA, were synthesized following well-established synthetic procedures [18, 19, 21]. The synthesis and the analytical data (HPLC and LC/MS) are provided in the “Supplementary information.” The structures are reported in Fig. 1.

¹⁷⁷Lu-labeling was performed at different conditions, depending on the ligand (Supplementary Table 1). Lipophilicity was assessed by determining the distribution coefficient (log D_{(pH 7.4)}) in 1-octanol/PBS (Supplementary Fig. 1).

Cell lines

HT-1080 and HEK-293 cells were transduced with the human FAP (hFAP). The production of lentiviral particles used for the transduction and the FACS gating strategy for the selection of monoclonal cell lines expressing FAP are provided in the “Supplementary information.” HT-1080.hFAP, a polyclonal cell line with heterogeneous and low FAP expression, and HEK-293.hFAP, a monoclonal cell line with high FAP expression (Supplementary Fig. 2), were used for the in vitro and in vivo evaluation. The two wild-type cell lines HT-1080.wt and HEK-293.wt were used to assess specificity.

Upon thawing, the cell lines were kept in culture in MEM supplemented with fetal bovine serum (10%) and penicillin-streptomycin (1%) at 37 °C and 5% CO₂.

Affinity determination and in vitro cellular uptake

The IC₅₀ of all the ligands against isolated hFAP protein was assessed by an inhibition assay following published protocols [15, 22] (Supplementary Information and Supplementary Fig. 3).

Cellular uptake and distribution were assessed in FAP-positive cell lines at different times points (15 min, 1 h, and 4 h) after exposure to the radioligand at 37 °C. Wild-type cells were used to assess unspecific uptake. Details are provided in the “Supplementary information” (Supplementary Fig. 4 and Supplementary Table 2).

Animal studies

All animal experiments were conducted in accordance with Swiss animal welfare laws and regulations under the license number 30515 granted by the Veterinary Office (Department of Health) of the Canton Basel-Stadt. Female athymic nude-Foxn1^nu/Foxn1⁺ mice (Envigo, Netherlands), 4–6 weeks old, were used for generating FAP( +)/FAP( −) dual xenografts. Mice were implanted subcutaneously with 5–12 × 10⁶ FAP( +) and FAP( −) cells suspended in 100 μL PBS on the right and left shoulder (imaging studies) or right and left flank (biodistribution studies), respectively. The tumors were allowed to grow until reaching a volume of 100–200 mm³.

SPECT/CT imaging studies

SPECT/CT images were acquired using a dedicated nanoSPECT/CT system (Bioscan, Mediso, Budapest, Hungary). Mice were injected intravenously via the tail vein with ~ 9–15 MBq (500 pmol) of the radioligand and euthanized after 4 h. Details on image acquisition and reconstruction parameters are described in the “Supplementary information.”

Biodistribution studies and AUC analysis

Mice were randomized (4–5/group), injected intravenously with the radioligand (100 µL/500 pmol/0.8–1 MBq), and euthanized at different time points (4 h, 24 h, 72 h, 120 h for HT-1080 and 4 h, 24 h, 72 h for HEK-293 xenografts, respectively) by CO₂ asphyxiation. Organs of interest and blood were collected, rinsed of excess blood, blotted dry, weighed, and counted in a γ-counter. The samples were counted against a suitably diluted aliquot of the injected solution as the standard, and the results were expressed as the percentage of the injected activity per gram of tissue (%I.A./g) ± standard deviation (SD).

The area under the time-activity curves (AUC) in the tumors were generated from the biodistribution data and expressed as (%I.A./g)*h. AUC of tumor-to-critical-organs ratios were also generated. The calculations were performed using GraphPad Prism 9. Ninety-five percent confidence interval (95% CI) and statistical analysis (p values) of the AUC data are presented in the “Supplementary information.”

Dosimetry

Non-decay corrected mice biodistribution data were used to generate time-activity curves for each radioligand. OLINDA/EXM 1.0 was used to integrate the fitted time-activity curves and to estimate the tumor doses and organ doses using the whole-body adult female model, as previously described [23]. For all calculations, the assumption was made that the mouse biodistribution, determined as the %I.A./organ, was the same as the human biodistribution.

Results

Synthesis, radiolabeling and lipophilicity

The FAP-binding moiety (S)-N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(methyl(3-(piperazin-1-yl)propyl)amino)quinoline-4-carboxamide was coupled to aspartic acid in order to allow the modification of FAPI-46. The free carboxylic acid was used to add Evans Blue, or for dimerization of the binding moiety, to generate FAPI-46-F1-EB and FAPI-46-F1D, respectively. The positive control FAPI-46-F1 was synthesized by attaching asparagine to the FAP-binding moiety. DOTA was conjugated to the N-terminal. FAPI-46-Ibu was synthesized by solid-phase synthesis from beta-diamino propionic acid which was coupled to DOTA first and then to the FAP-binding moiety. The peptide FAP-2286 was synthesized by solid-phase peptide synthesis, following published procedures [19]. All the ligands were obtained in high purity. The structures are shown in Fig. 1.

All ¹⁷⁷Lu-labeled ligands were prepared with apparent molar activities ranging from 8 up to 36 MBq/nmol, depending on the study, and radiochemical purity ≥ 93%.

The new monomer [¹⁷⁷Lu]Lu-FAPI-F1 was more hydrophilic than [¹⁷⁷Lu]Lu-FAPI-46 (log D = − 3.52 ± 0.04 vs − 2.99 ± 0.04, respectively), and similar to [¹⁷⁷Lu]Lu-FAP-2286 (− 3.43 ± 0.17). Dimerization introduced lipophilic characteristics similar to the conjugation of Evans Blue, while conjugation of ibuprofen led to the most lipophilic radioligand among all (log D = − 2.28 ± 0.06, − 2.65 ± 0.07, and − 0.63 ± 0.13 for [¹⁷⁷Lu]Lu-FAPI-F1D, [¹⁷⁷Lu]Lu-FAPI-F1-EB, and [¹⁷⁷Lu]Lu-FAPI-46-Ibu, respectively) (Supplementary Fig. 1).

Affinity and cellular distribution

All the ligands showed excellent inhibition properties on hFAP (Supplementary Fig. 3). FAPI-46-F1D and FAPI-46-Ibu showed enhanced inhibitory activity (IC₅₀ = 157.8 ± 14.5 and 39.4 ± 16.1 pM, respectively), while all the others showed reduced to very similar inhibitory activity (IC₅₀ = 265.6 ± 35.9, 634.3 ± 102.3, and 247.6 ± 71.1 pM for FAPI-46-F1, FAPI-46-EB, and FAP-2286, respectively), compared to FAPI-46 (IC₅₀ = 247.0 ± 17 pM).

All FAPI-46-based radioligands were internalized (35 up to 80% of the applied radioactivity at 4 h), with a minimum amount remaining on the cell surface (0.9 up to 4% at 4 h). [¹⁷⁷Lu]Lu-FAP-2286 displayed different cellular distribution, with rather low internalization (20–30% of the applied radioactivity at 4 h), and high cell surface binding (50–60% at 4 h) (Supplementary Fig. 4A-B and Supplementary Table 2).

SPECT/CT imaging

The visual assessment of SPECT/CT images at 4 h p.i. (Fig. 2) showed accumulation of all radioligands in the FAP-expressing tumors, with no accumulation in the wild-type tumors, with the exception of the [¹⁷⁷Lu]Lu-FAPI-46-EB in the HT1080.wt tumors. In the HT-1080-xenografts, [¹⁷⁷Lu]Lu-FAPI-46-F1D showed the highest FAP-tumor uptake, while [¹⁷⁷Lu]Lu-FAP-2286 presented the lowest, thought the best tumor-to-background contrast. In the HEK-293-xenografts, [¹⁷⁷Lu]Lu-FAP-2286 presented the highest FAP-tumor uptake, together with the best tumor-to-background contrast. In both tumor models, [¹⁷⁷Lu]Lu-FAPI-46-EB had the highest background. Quantification of the remaining activity in the body at 4 h p.i. (Supplementary Table 3) verified the fastest washout of the [¹⁷⁷Lu]Lu-FAP-2286 and the highest body retention of [¹⁷⁷Lu]Lu-FAPI-46-EB (6–8% vs 80–90% of the injected activity remained in the body at 4 h p.i., respectively), among all radioligands.

Biodistribution and AUC

Biodistribution results generated by gamma-counting harvested organs are provided in Tables 1, 2, 3, 4, and 5. Extended biodistribution data are provided in Supplementary Tables 4–8. Because [¹⁷⁷Lu]Lu-FAPI-46-F1 did not present any advantage compared to [¹⁷⁷Lu]Lu-FAPI-46 at 4 h and 24 h p.i. (Supplementary Table 9) the biodistribution was not further investigated.

Table 1

[¹⁷⁷Lu]Lu-FAPI-46 biodistribution results in HT-1080 and HEK-293 xenografts expressed as mean of the % injected activity per gram of tissue (%I.A./g) ± standard deviation (SD) (n = 4–5/group)

Organ	HT-1080 xenografts			HEK-293 xenografts
Organ	4 h	24 h	72 h	4 h	24 h	72 h
Blood	0.43 ± 0.04	0.03 ± 0.01	0.00 ± 0.00	0.65 ± 0.08	0.03 ± 0.01	0.00 ± 0.00
Lung	0.29 ± 0.03	0.05 ± 0.02	0.03 ± 0.00	0.41 ± 0.08	0.04 ± 0.01	0.01 ± 0.00
Liver	0.29 ± 0.02	0.21 ± 0.06	0.24 ± 0.05	0.35 ± 0.05	0.19 ± 0.07	0.10 ± 0.04
Kidney	1.19 ± 0.34	0.59 ± 0.05	0.39 ± 0.12	1.33 ± 0.19	0.38 ± 0.06	0.15 ± 0.10
Muscle	0.58 ± 0.38	0.09 ± 0.05	0.04 ± 0.03	0.49 ± 0.15	0.08 ± 0.03	0.01 ± 0.00
Femur	2.52 ± 0.38	0.61 ± 0.14	0.73 ± 0.08	2.22 ± 0.58	0.55 ± 0.22	0.19 ± 0.06
hFAP-tumor	9.63 ± 1.79	2.68 ± 0.74	1.58 ± 0.37	10.34 ± 4.55	3.39 ± 1.65	0.44 ± 0.11
wt-tumor	1.02 ± 0.18	0.35 ± 0.13	0.17 ± 0.04	1.40 ± 0.39	0.28 ± 0.07	0.05 ± 0.01

Table 2

[¹⁷⁷Lu]Lu-FAPI-46-F1D biodistribution results HT-1080 and HEK-293 xenografts expressed as mean of the % injected activity per gram of tissue (%I.A./g) ± standard deviation (SD) (n = 4–6/group)

Organ	HT-1080			HEK-293
Organ	4 h	24 h	72 h	4 h	24 h	72 h
Blood	1.21 ± 0.22	0.60 ± 0.05	0.04 ± 0.01	1.51 ± 0.28	0.59 ± 0.08	0.05 ± 0.01
Lung	0.87 ± 0.21	0.53 ± 0.01	0.18 ± 0.03	0.93 ± 0.13	0.55 ± 0.07	0.25 ± 0.04
Liver	0.67 ± 0.16	1.37 ± 0.04	1.23 ± 0.27	0.83 ± 0.25	1.35 ± 0.15	1.66 ± 0.31
Kidney	1.25 ± 0.08	1.02 ± 0.16	0.87 ± 0.20	1.28 ± 0.19	0.94 ± 0.06	0.73 ± 0.06
Muscle	1.35 ± 0.43	0.88 ± 0.10	0.41 ± 0.21	1.05 ± 0.27	0.80 ± 0.11	0.41 ± 0.06
Femur	4.91 ± 0.75	2.89 ± 0.08	2.02 ± 0.32	5.19 ± 0.86	3.04 ± 0.27	2.09 ± 0.23
hFAP-tumor	10.47 ± 2.47	6.42 ± 0.89	3.57 ± 0.73	17.16 ± 4.63	5.89 ± 1.29	1.43 ± 0.20
wt-tumor	2.26 ± 0.32	2.57 ± 0.42	1.14 ± 0.38	3.27 ± 1.89	1.99 ± 0.26	1.41 ± 0.38

Table 3

[¹⁷⁷Lu]Lu-FAPI-46-Ibu biodistribution results HT-1080 and HEK-293 xenografts expressed as mean of the % injected activity per gram of tissue (%I.A./g) ± standard deviation (SD) (n = 4/group)

Organ	HT-1080			HEK-293
Organ	4 h	24 h	72 h	4 h	24 h	72 h
Blood	1.07 ± 0.10	0.14 ± 0.03	0.01 ± 0.00	1.00 ± 0.18	0.10 ± 0.01	0.00 ± 0.00
Lung	0.83 ± 0.07	0.21 ± 0.03	0.07 ± 0.02	1.88 ± 2.29	0.15 ± 0.01	0.04 ± 0.01
Liver	0.96 ± 0.08	1.02 ± 0.70	0.50 ± 0.02	0.75 ± 0.11	0.58 ± 0.35	0.35 ± 0.04
Kidney	1.80 ± 0.15	1.15 ± 0.19	0.54 ± 0.11	1.33 ± 0.17	0.81 ± 0.11	0.25 ± 0.03
Muscle	0.97 ± 0.25	0.43 ± 0.28	0.12 ± 0.07	0.87 ± 0.36	0.28 ± 0.08	0.07 ± 0.03
Femur	3.62 ± 0.04	1.12 ± 0.12	0.51 ± 0.09	2.46 ± 0.88	0.81 ± 0.11	0.33 ± 0.08
hFAP-tumor	8.40 ± 1.97	5.09 ± 0.64	1.55 ± 0.58	5.03 ± 2.84	3.14 ± 0.49	0.88 ± 0.40
wt-tumor	1.96 ± 0.36	1.00 ± 0.25	0.28 ± 0.05	1.86 ± 1.25	0.52 ± 0.11	0.18 ± 0.05

Table 4

[¹⁷⁷Lu]Lu-FAPI-46-EB biodistribution results HT-1080 and HEK-293 xenografts expressed as mean of the % injected activity per gram of tissue (%I.A./g) ± standard deviation (SD) (n = 4/group)

Organ	HT-1080			HEK-293
Organ	4 h	24 h	72 h	4 h	24 h	72 h
Blood	11.59 ± 0.46	5.47 ± 0.85	1.63 ± 0.19	13.16 ± 2.19	6.85 ± 0.61	1.18 ± 0.05
Lung	5.45 ± 0.23	3.27 ± 0.60	1.64 ± 0.08	6.45 ± 1.19	3.98 ± 0.44	1.45 ± 0.06
Liver	2.80 ± 0.26	2.66 ± 0.31	2.78 ± 0.48	3.06 ± 0.36	3.05 ± 0.12	2.29 ± 0.23
Kidney	4.33 ± 0.12	5.02 ± 0.59	5.97 ± 0.49	4.70 ± 1.03	6.67 ± 0.67	4.86 ± 0.72
Muscle	1.31 ± 0.07	1.17 ± 0.13	0.85 ± 0.19	1.61 ± 0.17	1.39 ± 0.27	0.59 ± 0.25
Femur	2.35 ± 0.24	2.09 ± 0.21	1.34 ± 0.13	2.43 ± 0.26	2.51 ± 0.30	1.08 ± 0.24
hFAP-tumor	5.02 ± 0.29	5.44 ± 1.03	4.16 ± 0.19	12.58 ± 2.83	16.69 ± 1.01	6.75 ± 1.06
wt-tumor	3.70 ± 0.72	3.56 ± 0.76	3.75 ± 1.02	3.75 ± 0.40	4.25 ± 0.47	2.10 ± 0.07

Table 5

[¹⁷⁷Lu]Lu-FAP-2286 biodistribution results HT-1080 and HEK-293 xenografts expressed as mean of the % injected activity per gram of tissue (%I.A./g) ± standard deviation (SD) (n = 4/group)

Organ	HT-1080			HEK-293
Organ	4 h	24 h	72 h	4 h	24 h	72 h
Blood	0.03 ± 0.01	0.00 ± 0.00	0.00 ± 0.00	0.04 ± 0.01	0.00 ± 0.00	0.00 ± 0.00
Lung	0.08 ± 0.01	0.03 ± 0.01	0.01 ± 0.00	0.07 ± 0.00	0.02 ± 0.00	0.01 ± 0.00
Liver	0.11 ± 0.02	0.08 ± 0.01	0.05 ± 0.01	0.11 ± 0.01	0.09 ± 0.00	0.03 ± 0.01
Kidney	5.15 ± 0.65	3.62 ± 0.51	1.58 ± 0.51	3.98 ± 0.42	2.33 ± 0.48	0.72 ± 0.22
Muscle	0.04 ± 0.01	0.02 ± 0.01	0.01 ± 0.00	0.06 ± 0.03	0.02 ± 0.01	0.01 ± 0.01
Femur	0.15 ± 0.05	0.10 ± 0.01	0.16 ± 0.06	0.27 ± 0.04	0.20 ± 0.01	0.04 ± 0.02
hFAP-tumor	3.42 ± 1.06	1.67 ± 0.50	0.64 ± 0.22	22.99 ± 3.13	13.49 ± 1.95	4.05 ± 0.99
wt-tumor	0.10 ± 0.01	0.08 ± 0.01	0.04 ± 0.01	0.28 ± 0.13	0.13 ± 0.05	0.02 ± 0.02

In the low FAP-expressing model HT-1080.hFAP, the tumor uptake at 4 h p.i. (peak uptake) followed the order [¹⁷⁷Lu]Lu-FAPI-46-F1D ≥ [¹⁷⁷Lu]Lu-FAPI-46 ≥ [¹⁷⁷Lu]Lu-FAPI-46-Ibu > [¹⁷⁷Lu]Lu-FAPI-46-EB > [¹⁷⁷Lu]Lu-FAP-2286 (10.47 vs 9.63 vs 8.40 vs 5.02 vs 3.42%I.A./g). However, after 72 h, only the [¹⁷⁷Lu]Lu-FAPI-46-EB retained highly in the tumor (83%), followed by [¹⁷⁷Lu]Lu-FAPI-46-F1D (34%). Less than 20% retained in the tumor for the other three radioligands. Interestingly, [¹⁷⁷Lu]Lu-FAPI-46-EB showed high and persistent accumulation in HT1080.wt tumors; e.g., at 4 h p.i. 74% of the uptake found in HT1080.hFAP was determined in the HT1080.wt. This was ~ 20% for [¹⁷⁷Lu]Lu-FAPI-46-F1D and [¹⁷⁷Lu]Lu-FAPI-46-Ibu, significantly lower for [¹⁷⁷Lu]Lu-FAPI-46 (~ 10%), and almost negligible for [¹⁷⁷Lu]Lu-FAP-2286 (~ 3%).

In the high FAP-expressing model HEK-293.hFAP, the tumor uptake at 4 h p.i. (peak uptake) followed another order: [¹⁷⁷Lu]Lu-FAP-2286 > [¹⁷⁷Lu]Lu-FAPI-46-F1D > [¹⁷⁷Lu]Lu-FAPI-46-EB ≥ [¹⁷⁷Lu]Lu-FAPI-46 > [¹⁷⁷Lu]Lu-FAPI-46-Ibu (22.99 vs 17.16 vs 12.58 vs 10.34 vs 5.03%I.A./g). After 72 h, [¹⁷⁷Lu]Lu-FAPI-46-EB showed the highest tumor retention (54%), followed by [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁷⁷Lu]Lu-FAPI-46-Ibu (18%). [¹⁷⁷Lu]Lu-FAPI-46-F1D and [¹⁷⁷Lu]Lu-FAPI-46 retained in the tumor only by ~ 8% and ~ 4%, respectively. Regarding specificity, [¹⁷⁷Lu]Lu-FAPI-46-EB and [¹⁷⁷Lu]Lu-FAPI-46-Ibu showed the highest nonspecific binding; e.g. at 4 h p.i. 30–40% of the uptake found in HEK293.hFAP was determined in HEK293.wt. This was 19% for [¹⁷⁷Lu]Lu-FAPI-46-F1D, ~ 14% for [¹⁷⁷Lu]Lu-FAPI-46, and only 1% for [¹⁷⁷Lu]Lu-FAP-2286.

Concerning total body distribution and pharmacokinetics, the two monomers [¹⁷⁷Lu]Lu-FAPI-46 and [¹⁷⁷Lu]Lu-FAP-2286 showed significantly lower background activity. [¹⁷⁷Lu]Lu-FAP-2286 presented the lowest background, with the exception the kidney uptake. Among the other three radioligands, [¹⁷⁷Lu]Lu-FAPI-46-Ibu showed lower background (still higher than the monomers), followed by [¹⁷⁷Lu]Lu-FAPI-46-F1D. [¹⁷⁷Lu]Lu-FAPI-46-EB showed the highest background activity at all investigated time points.

The AUC of the tumor uptake over time was assessed from the biodistribution data as a surrogate of the radiation dose delivered to the tumors (Fig. 3A and B and Supplementary Table 10). In the low FAP-expressing tumors, [¹⁷⁷Lu]Lu-FAPI-46-F1D and the two albumin binder conjugates, [¹⁷⁷Lu]Lu-FAPI-46-Ibu and [¹⁷⁷Lu]Lu-FAPI-46-EB, presented the highest AUCs. In the high FAP-expressing tumors, [¹⁷⁷Lu]Lu-FAPI-46-EB and [¹⁷⁷Lu]Lu-FAP-2286 had the highest tumor AUC. Interestingly, [¹⁷⁷Lu]Lu-FAPI-46-EB showed 2.6-fold increase in the high vs low FAP-expressing tumors (880 vs 345%I.A./g*h, respectively) and [¹⁷⁷Lu]Lu-FAP-2286 an increase of 7.4-fold (832 vs 113%I.A./g*h, respectively). No difference was observed in the AUC of [¹⁷⁷Lu]Lu-FAPI-46 and [¹⁷⁷Lu]Lu-FAPI-46-F1D between the two tumor models.

The AUCs of the tumor-to-critical-organs ratios were assessed as indicators of the therapeutic index (Figs. 4 and 5). With the exception of the tumor-to-kidneys ratio, [¹⁷⁷Lu]Lu-FAP-2286 presented the most favorable tumor-to-critical-organs ratios over time in both tumor models, as indicated by the AUC of tumor-to-blood, tumor-to-liver, and tumor-to-femur ratios.

Dosimetry

The dosimetry estimates for the critical organs and the FAP-expressing tumors are reported in Table 6. The low FAP-expressing tumors received the highest radiation dose from [¹⁷⁷Lu]Lu-FAPI-46-F1D, [¹⁷⁷Lu]Lu-FAPI-46-Ibu, and [¹⁷⁷Lu]Lu-FAPI-46-EB (3.67, 3.64, and 7.52 mGy/MBq, respectively), while the high FAP-expressing tumors received the highest dose from [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁷⁷Lu]Lu-FAPI-46-EB (6.76 and 11.3 mGy/MBq, respectively). Regarding the critical organs, the absorbed dose in the red marrow was highest for [¹⁷⁷Lu]Lu-FAPI-46-EB, followed by [¹⁷⁷Lu]Lu-FAPI-46-Ibu (2.79E-02 and 6.50E-03 mGy/MBq, respectively), while [¹⁷⁷Lu]Lu-FAPI-46-F1D delivered 11 and 2.6 times lower dose, respectively, though higher than [¹⁷⁷Lu]Lu-FAPI-46 and [¹⁷⁷Lu]Lu-FAP-2286. The absorbed dose to the kidneys was highest for [¹⁷⁷Lu]Lu-FAPI-46-EB (3.71E + 00 mGy/MBq), followed by [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁷⁷Lu]Lu-FAPI-46-F1D that delivered doses of one order of magnitude lower (2.04E-01 and 1.11E-01 mGy/MBq, respectively). Among all radioligands, the lowest dose to the kidneys was delivered by [¹⁷⁷Lu]Lu-FAPI-46 (4.69E-02 mGy/MBq) and the lowest dose to the red marrow and the liver was delivered by [¹⁷⁷Lu]Lu-FAP-2286 (1.78E-04 and 4.21E-03 mGy/MBq, respectively).

Table 6

Radiation dosimetry estimation in tumors and critical organs expressed as mean absorbed dose (mGy/MBq). Results were obtained with OLINDA/EXM 1.0 by integrating the fitted time-activity curves

Organ	[¹⁷⁷Lu]Lu-FAPI-46	[¹⁷⁷Lu]Lu-FAPI-46-F1D	[¹⁷⁷Lu]Lu-FAPI-46-Ibu	[¹⁷⁷Lu]Lu-FAPI-46-EB	[¹⁷⁷Lu]Lu-FAP-2286
Kidneys	4.69E-02	1.11E-01	6.75E-02	3.71E+00	2.04E-01
Liver	3.58E-02	1.18E-01	4.25E-02	3.23E-01	4.21E-03
Red marrow	4.05E-04	2.53E-03	6.50E-03	2.79E-02	1.78E-04
HT-1080.hFAP tumor	1.73E+00	3.67E+00	3.64E+00	7.25E+00	8.62E-01
HEK-293.hFAP tumor	1.72E+00	2.31E+00	1.75E+00	1.13E+01	6.76E+00

Discussion

The therapeutic value of FAP-targeting radioligands is harmed mainly due to their short tumor residence time [7, 11, 24]. Three different strategies have been proposed for prolonging tumor residence time: (a) multimerization of the FAP-binding moiety [15, 16, 25], (b) conjugation of an albumin binder [17, 18, 2826-], and (c) peptide-based structures as an alternative to small molecules [19, 20]. Nevertheless, a direct comparison among them is still missing. We, therefore, synthesized and tested head-to-head a panel of FAP radioligands representing all the above-mentioned strategies, including the new albumin-binder conjugate [¹⁷⁷Lu]Lu-FAPI-46-Ibu. Our aim was to identify the strengths and limitations of the different strategies that need to be considered in the development of FAP-targeting radiotherapeutics.

In vitro, all radioligands showed very high affinity to hFAP, with a certain variation among them, and IC₅₀ values in the picomolar range. This allowed a fair comparison in vivo regarding FAP-targeting. Differences were observed in their cellular distribution. All [¹⁷⁷Lu]Lu-FAPI-46-based radioligands were almost entirely internalized, while [¹⁷⁷Lu]Lu-FAP-2286 remained mainly on the cell surface.

Focusing on the first strategy of dimerization, [¹⁷⁷Lu]Lu-FAPI-46-F1D presented a higher and more persistent uptake in the tumor, compared to the monomer [¹⁷⁷Lu]Lu-FAPI-46, independent of the tumor model. This is in line with the recently published studies on FAP-targeting dimers, such as BiOncoFAP [15], DOTAGA.(SA.FAPi)₂ [16, 29, 30], DOTA-2P(FAPi)₂ [25, 31], and ND-bisFAPI [14]. Undoubtfully, this observation supports the use of multimers for FAP-targeting radiotherapeutics per se. Evidently, total body distribution and pharmacokinetics are just as important as tumor uptake. In our study, it was shown that dimerization doubled the radiation dose delivered to the tumor, but also increased the dose to non-targeted organs, especially in blood, femur, liver, and kidneys, and the overall background activity, suggesting higher toxicity. The first-in-human dosimetry study of [¹⁷⁷Lu]Lu-DOTAGA.(SA.FAPi)₂ vs the monomer [¹⁷⁷Lu]Lu-DOTAGA.SA.FAPi demonstrated a significantly longer tumor retention, accompanied by a significantly higher whole-body effective half-life and uptake in healthy organs (e.g., colon and kidneys) [16]. No data about the therapeutic efficacy are available so far [16].

Focusing on the second strategy of the albumin binder conjugation, our study indicated that the outcome heavily depends on the albumin binder moiety of choice. [¹⁷⁷Lu]Lu-FAPI-46-EB was found to be highly concentrated in the blood, while [¹⁷⁷Lu]Lu-FAPI-46-Ibu presented a much faster clearance (1/10th compared with [¹⁷⁷Lu]Lu-FAPI-46-EB at 4 h p.i. and even less at later time points). A recent study on FAPI-04 conjugates with the albumin binders 4-(p-iodophenyl)butyric acid ([¹⁷⁷Lu]Lu-TEFAPI-06) and Evans Blue ([¹⁷⁷Lu]Lu-TEFAPI-07) also indicated significant differences between the two moieties [17]. The blood concentration of the [¹⁷⁷Lu]Lu-TEFAPI-06 was higher compared with [¹⁷⁷Lu]Lu-TEFAPI-07 (e.g., 12.3 vs 5.64%IA/g at 24 h p.i.), but the tumor uptake and retention was the same for both. Our biodistribution data with [¹⁷⁷Lu]Lu-FAPI-46-EB are in line with the EB conjugate [¹⁷⁷Lu]Lu-TEFAPI-07 [17]. In our study, between the two albumin binders, the new [¹⁷⁷Lu]Lu-FAPI-46-Ibu did not provide any advantage over [¹⁷⁷Lu]Lu-FAPI-46, while [¹⁷⁷Lu]Lu-FAPI-46-EB had serious limitations regarding specificity and total body radiation exposure. Overall, none of the two conjugates showed clear advantages over [¹⁷⁷Lu]Lu-FAPI-46. Similar results were found with FAPI-02 EB conjugates via PEGylation vs unmodified FAPI-02 [18].

The third strategy of using peptides as an alternative to small molecules showed to be the best choice in tumors highly expressing FAP. [¹⁷⁷Lu]Lu-FAP-2286 had the highest and also durable uptake in HEK293.hFAP tumors, and the lowest uptake in healthy organs, with the exception of the kidneys. Our results confirmed previous findings with [¹⁷⁷Lu]Lu-FAP-2286 regarding biodistribution and tumor retention in HEK-293.hFAP xenografts [19]. Surprisingly, in the HT-1080.hFAP xenografts the tumor uptake of [¹⁷⁷Lu]Lu-FAP-2286 was significantly lower, being the lowest among all studied radioligands. Nevertheless, the AUC of the tumor-to-critical-organs ratio was in favor of [¹⁷⁷Lu]Lu-FAP-2286, despite the lowest tumor uptake. The exception remained the tumor-to-kidneys ratio, rendering kidneys the critical organ. However, the estimated absorbed dose of [¹⁷⁷Lu]Lu-FAP-2286 to the kidneys was in the same level as [¹⁷⁷Lu]Lu-DOTA-TATE (2.04E-01 vs 2.13E-01 mGy/MBq), assessed by the same methodology [23], while its red marrow dose was lower (1.78E-04 vs 1.25E-03 mGy/MBq, respectively). Preliminary human data with [¹⁷⁷Lu]Lu-FAP-2286 indicated that the delivered dose to the whole body, bone marrow and kidneys were comparable to that of Pluvicto and Lutathera ([¹⁷⁷Lu]Lu-DOTA-TATE) [20]. The same study showed that the tumor half-life of [¹⁷⁷Lu]Lu-FAP-2286 is shorter than the above-mentioned approved radiotherapeutics, even though longer compared to the FAPI-based small molecules [20].

Last, but not least, we tried to understand the discrepancy between HT-1080.hFAP and HEK-293.hFAP on the in vivo uptake of [¹⁷⁷Lu]Lu-FAP-2286. Our initial hypothesis was that a saturation level was reached in HT-1080.hFAP tumors with the injected mass of 500 pmol used in the study, given the low expression level of FAP. We, therefore, evaluated the biodistribution of [¹⁷⁷Lu]Lu-FAP-2286 and of [¹⁷⁷Lu]Lu-FAPI-46 in HT-1080.hFAP xenografts using tenfold less amount (Supplementary Table 11). The results using 50 pmol instead of 500 pmol indicated that no saturation was reached. To determine the saturation effect on the two tumors, an ex vivo blocking study was performed for [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁷⁷Lu]Lu-FAPI-46 in both tumor models. In each case, 60-fold excess of the non-labeled ligand was administered 5 min before the injection of the corresponding radioligand. While in the HT-1080.hFAP tumors a complete inhibition of the radioligand uptake was observed, in the high-expressing FAP cell line HEK-293.hFAP tumors the inhibition was lower, still significantly lower when compared to the radioligand uptake without the blocking (Supplemental Fig. 5 and 6). These results indicate that the HEK-293.hFAP model has available amounts of hFAP that require more than 30.5 nmol of FAP ligands to be completely occupied. The in vitro autoradiography performed on HT-1080.hFAP and HEK-293.hFAP tumor slides after incubation with [¹⁷⁷Lu]Lu-FAPI-46 and [¹⁷⁷Lu]Lu-FAP-2286 with and without the presence of 10,000-fold excess of the non-labeled ligand (Supplemental Fig. 7) corroborated these results. In addition, the autoradiography confirmed the difference observed in vivo between the [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁷⁷Lu]Lu-FAPI-46 in the two tumor models. Our second hypothesis was that the two classes of the studied ligands, FAPI small molecules and a cyclic peptide, may present different binding sites as they are structurally very different. To test this hypothesis, we performed some preliminary in vitro experiments on cell membranes. We observed lower blocking efficiency when FAPI-46 was used to block the binding of [¹⁷⁷Lu]Lu-FAP-2286, compared to its efficiency to block [¹⁷⁷Lu]Lu-FAPI-46 (data not shown). This is an indication that the two ligands might present different binding sites. However, further and more sophisticated experiments have to be designed for testing this hypothesis.

The presented results on two cell lines with distinct expression and homogeneity levels of FAP (polyclonal vs high-expressing monoclonal, Supplementary Fig. 3) underlined the importance of the tumor model in assessing FAP-targeting ligands. Different target density on the cell surface may have a profound impact on the receptor occupancy, affecting the total uptake of the radioligand [32]. Moreover, since FAP is known to be active upon homodimerization, a higher receptor density may promote oligomerization, affecting the radioligand binding [33]. Furthermore, it is known that the glycosylation pattern can vary among different cell lines expressing the same protein, rendering the binding site of radioligands less accessible [34]. Complementary to our second hypothesis, we may speculate that homo/oligo-merization and/or glycosylation pattern is more relevant for the binding of the FAP-targeting peptide-based structures than the quinoline-based small-molecule inhibitors. This might explain why the uptake of the [¹⁷⁷Lu]Lu-FAP-2286 was significantly impacted by the FAP-expression level and density, which was not the case for the FAPI-46-based radioligands. Nevertheless, as far as we know, no data are available in the literature to support this hypothesis. Finally, using cell lines with distinct characteristics and FAP expression levels may elucidate the interactions of structurally different radioligands with FAP.

To the best of our knowledge, this is the only study so far providing a fair comparison among the different structural designs. We choose representative radioligands from each strategy with very similar behavior to corresponding radioligands reported in the literature [15, 18, 19, 21]. The results captured the typical features of each strategy design that impart to the targeting ligand and give hints for the design of FAP-targeting radio-therapeutics.

In conclusion, this head-to-head comparison indicated that dimerization of the FAPI small molecules and the cyclic peptide are two very promising strategies for enhancing tumor radiation dose, compared to FAPI monomers. In addition, the present study indicated that the therapeutic outcome of using albumin binders heavily depends on the selection of the albumin binding moiety. Considering the combination of tumor radiation dose (tumor uptake and residence), in vivo specificity, and tumor-to-background ratios (therapeutic index), the peptide showed certain advantages. However, the discrepancy of its performance between the different tumor models needs further investigation for concluding on any overall superiority compared to the other strategies and to FAPI small molecules.

Acknowledgements

We thank Lisa McDougall for her support with the SPECT/CT experiments and dosimetry.

Declarations

Ethics approval

Competing interests

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

Jetzt testen ²

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 1.30 MB)

van der Heide CD, Dalm SU. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur J Nucl Med Mol Imaging. 2022;49:4616–41.CrossRefPubMedPubMedCentral

Kalinski P, Talmadge JE. Tumor Immuno-Environment in Cancer Progression and Therapy. In: Kalinski P, editors. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology, vol 1036. Cham: Springer; 2017. https://doi.org/10.1007/978-3-319-67577-0_1

Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30:7452.

Arcucci A, Ruocco MR, Granato G, Sacco AM, Montagnani S. Cancer: An oxidative crosstalk between solid tumor cells and cancer associated fibroblasts. Biomed Res Int. 2016;2016:4502846. https://doi.org/10.1155/2016/4502846

Coto-Llerena M, Ercan C, Kancherla V, Taha-Mehlitz S, Eppenberger-Castori S, Soysal SD, et al. High expression of FAP in colorectal cancer is associated with angiogenesis and immunoregulation processes. Front Oncol. 2020;10:1–12.CrossRef

Expression of PIP5K1A in cancer - The Human Protein Atlas. Available from: http://www.proteinatlas.org/ENSG00000143398-PIP5K1A/cancer

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.CrossRefPubMedPubMedCentral

Calais J. FAP: the next billion dollar nuclear theranostics target? J Nucl Med. 2020;61:163–5.CrossRefPubMed

Huang R, Pu Y, Huang S, Yang C, Yang F, Pu Y, et al. FAPI-PET/CT in cancer imaging: a potential novel molecule of the century. Front Oncol. 2022;12:1–12.

10.

Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of 68ga-fapi-46 pet imaging in cancer patients. J Nucl Med. 2020;61:1171–7.CrossRefPubMedPubMedCentral

11.

Kaghazchi F, Aghdam RA, Haghighi S, Vali R, Adinehpour Z. 177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma. Clin Nucl Med. 2022;47:E243–5.CrossRefPubMed

12.

Kratochwil C, Giesel FL, Rathke H, Fink R, Dendl K, Debus J, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021;48:3011–3.

13.

Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients. J Nucl Med. 2022;63:727–34.PubMedPubMedCentral

14.

Li H, Ye S, Li Li, Zhong J, Yan Q, Zhong Y, et al. 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022;49:2705–15.

15.

Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, et al. A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake. J Nucl Med. 2022;63:1852–8.CrossRefPubMedPubMedCentral

16.

Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177lu]lu-dota.Sa.fapi and [177lu]lu-dotaga.(sa.fapi)2. Pharmaceuticals. 2021;14:1212.

17.

Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy. J Nucl Med. 2022;63:952–8.CrossRefPubMedPubMedCentral

18.

Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12:422–33.CrossRefPubMedPubMedCentral

19.

Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651–67.CrossRefPubMedPubMedCentral

20.

Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415–23.CrossRefPubMedPubMedCentral

21.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421–9.CrossRefPubMedPubMedCentral

22.

Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A. 2021;118:e2101852118.

23.

Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, pharmacokinetics, and dosimetry of 177Lu-,90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: The mass effect. J Nucl Med. 2017;58:1435–41.CrossRefPubMed

24.

Assadi M, Rekabpour SJ, Jafari E, Divband GA, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177Lu-Fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study. Clin Nucl Med. 2021;46:e523–30.CrossRefPubMed

25.

Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of 68Ga-labeled FAPI dimer. J Nucl Med. 2022;63:862–8.CrossRefPubMedPubMedCentral

26.

Younis MH, Malih S, Lan X, Rasaee MJ, Cai W. Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond. Eur J Nucl Med Mol Imaging. 2022;49:1773–7.CrossRefPubMedPubMedCentral

27.

Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, et al. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2022;49:1985–96.CrossRefPubMed

28.

Lindeman SD, Mukkamala R, Horner A, Tudi P, Booth OC, Huff RR, et al. Fibroblast activation protein targeted radioligand therapy for treatment of solid tumors. J Nucl Med. 2023;64:759–66.CrossRefPubMed

29.

Ballal S, Yadav M, Kumari S, Roesch F, Tripathi M, Tupalli A, et al. First clinical experience and initial outcomes of Lu-DOTAGA.(SA.FAPi) therapy in patients with end-stageradioiodine-refractory differentiated thyroid cancer: ASalvage treatment option. J Nucl Med. 2021;62 (supplement 1):1701.

30.

Moon ES, Ballal S, Yadav MP, Bal C, Van Rymenant Y, Stephan S, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021;11:476–91.PubMedPubMedCentral

31.

Zhao L, Chen J, Pang Y, Fang J, Fu K, Meng L, et al. Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy. Mol Pharm. 2022;19:3640–51.CrossRefPubMed

32.

Jarvis GE, Thompson AJ. Evidence for an effect of receptor density on ligand occupancy and agonist EC 50. Sci Rep. 2019;9:1–12.CrossRef

33.

Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783–803.

34.

Goh JB, Ng SK. Impact of host cell line choice on glycan profile. Crit Rev Biotechnol. 2018;38:851–67.CrossRefPubMed

Titel: Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
verfasst von: Jacopo Millul
Lennart Koepke
Gaonkar Raghuvir Haridas
Konstantin M. J. Sparrer
Rosalba Mansi
Melpomeni Fani
Publikationsdatum: 01.06.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06272-7

Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma

Image of the Month

Correction to: One‑stop [18F]FDG and [68Ga]Ga‑DOTA‑FAPI‑04 total‑body PET/CT examination with dual‑low activity: a feasibility study

Correction

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma

Original Article

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)

Open Access
Original Article

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

Original Article

Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer

Open Access
Original Article

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Supplementary information

Publisher's note

Introduction

Material and methods

Synthesis, radiolabeling, and log D determination

Cell lines

Affinity determination and in vitro cellular uptake

Animal studies

SPECT/CT imaging studies

Biodistribution studies and AUC analysis

Dosimetry

Results

Synthesis, radiolabeling and lipophilicity

Affinity and cellular distribution

SPECT/CT imaging

Biodistribution and AUC

Dosimetry

Discussion

Acknowledgements

Declarations

Ethics approval

Competing interests

Publisher's note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Radiologie

Supplementary Information

Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma

Correction to: One‑stop [18F]FDG and [68Ga]Ga‑DOTA‑FAPI‑04 total‑body PET/CT examination with dual‑low activity: a feasibility study

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer